Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiparasitic agents.

J E Rosenblatt1

  • 1Division of Infectious Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905.

Mayo Clinic Proceedings
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

New antiparasitic drugs offer improved therapies, but challenges like drug resistance, limited FDA approval, and toxicity in specific populations persist. Effective treatments are available for many infections, though some remain difficult to manage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-transmitted toxoplasmosis in liver transplant recipients: a case report and literature review.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Clinical microbiology reviews·2006
Same author

Comparison of the Roche LightCycler vanA/vanB detection assay and culture for detection of vancomycin-resistant enterococci from perianal swabs.

Journal of clinical microbiology·2004
Same author

Real-time PCR method for detection of Encephalitozoon intestinalis from stool specimens.

Journal of clinical microbiology·2002
Same author

Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2002
Same author

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2002
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • * Parasitic infections represent a significant global health challenge, necessitating continuous development of effective therapeutic agents.
  • * Antimicrobial resistance, particularly in malaria, and limited regulatory approval impact treatment accessibility and efficacy.

Context:

  • * The landscape of parasitic infection treatment is evolving with new drug introductions.
  • * Existing therapies face limitations including resistance, FDA approval status, and safety concerns in vulnerable populations like pregnant women and children.

Purpose:

  • * To review current therapeutic agents for various parasitic infections.
  • * To highlight challenges in parasitic disease treatment, including drug resistance and safety profiles.
  • * To discuss the efficacy and limitations of both established and novel antiparasitic drugs.

Summary:

  • * Effective treatments exist for malaria (quinine/Fansidar, mefloquine), amebiasis/giardiasis (metronidazole), and helminthic infections (benzimidazoles, ivermectin, praziquantel).

Related Experiment Videos

  • * Emerging agents like azithromycin show promise for cryptosporidiosis, while therapies for leishmaniasis and trypanosomiasis remain complex and often toxic.
  • * Drug resistance in Plasmodium falciparum and limited FDA approval for certain agents (e.g., mefloquine for treatment, metronidazole for giardiasis) pose significant hurdles.

    • Impact:

    • * Advances in antiparasitic drug development offer improved patient outcomes for numerous infections.
    • * Addressing drug resistance and expanding FDA-approved treatment options are crucial for global public health.
    • * The introduction of agents like ivermectin and praziquantel has transformed the management of specific parasitic diseases.